Pengli Bio Completes Nearly $100M Financing to Build a World-Class Preclinical R&D Service Platform

VCBeat has learned that Peng Li Biomedical Technology (Shanghai) Co., Ltd. (“Peng Li Bio”) recently announced the completion of a new round of financing, with total proceeds nearing USD 100 million. The round was co-led by existing investors GL Ventures and HongShan, with participation from TOTAL AMPLE LIMITED, Yunion Healthcare Ventures, Lichen Investment, Yuanlai Investment, GT Capital, and Suzhou International Development Venture Capital. Existing investors Prosperico Ventures and Med-Fine Capital also made additional investments.

The funds will be utilized to further expand the preclinical pharmacology, efficacy, and bioanalysis service platform; upgrade laboratory facilities; enrich a comprehensive portfolio of animal models; cover a broader range of disease areas and advanced therapeutic modalities; and enhance the global service network. The aim is to build a world-class preclinical R&D service platform that facilitates efficient innovation in pharmaceuticals and medical devices both domestically and internationally.

Duan Jifeng, Founder, Chairman, and CEO of Peng Li Biomedicalstated: “We are deeply grateful to all investors, particularly the top-tier investment institutions in the industry, for their recognition and trust in Peng Li Biomedical. Adhering to a craftsman’s spirit in scientific research, Peng Li Biomedical has remained dedicated to continuously enhancing the quality and level of its services in pharmacology, efficacy evaluation, and bioanalysis. Since completing its Series A financing in 2017, the company has maintained high-speed growth every year. It has established business collaborations with nearly 1,000 innovative pharmaceutical and medical device companies both domestically and internationally, becoming a well-known brand in China’s pharmacology and efficacy evaluation sector. Peng Li Biomedical has reached international first-class standards in areas such as non-human primates, humanized animal models, and immunology applications. Its service scope covers innovative product lines including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), nucleic acid drugs, protein/peptide therapeutics, cell therapy, and gene therapy. With this round of financing, Peng Li Biomedical will continue to increase R&D innovation, improve service capabilities, and strive to become a globally renowned R&D service provider.”

Peng Li Biomedical, established in 2008, is a leading domestic provider of comprehensive preclinical pharmacological efficacy evaluation and bioanalytical services. It boasts China’s most comprehensive immunoinflammatory pharmacology evaluation platform, an internationally leading non-human primate efficacy evaluation platform, cutting-edge platforms for tumor immuno-oncology and humanized animal model efficacy evaluation, as well as an international-standard platform for bone disease research and Class III medical device testing.

Peng Li Biomedical operates laboratories in Shanghai’s Pudong and Fengxian districts that strictly adhere to AAALAC and ILAC standards, with a total area of nearly 30,000 square meters. The company has completed nearly 300 new drug application projects for both domestic and international clients, possesses over 500 validated disease animal models, and provides services across multiple therapeutic areas, including inflammation and autoimmune diseases, oncology and tumor immunology, hepatic metabolic disorders, ophthalmic diseases, bone metabolism, and orthopedics. Its controlled subsidiary, Peng Li Testing, is the first company in Shanghai to obtain CNAS accreditation for preclinical animal testing services evaluating the functionality and safety of Class III medical devices. Peng Li Biomedical was selected for the Shanghai Science and Technology Little Giant Program in 2020 and was awarded the title of “Little Giant” in the third batch of specialized, refined, distinctive, and innovative enterprises announced by the State Council in 2021.